APVO

Aptevo Therapeutics Inc.

1.74 USD

Last updated Sep 4, 20:27 UTC

Yesterday HIGH

$2.18

Yesterday LOW

$1.37

52w HIGH

$48.78

52w LOW

$1.37

EPS

-5.31

PE

-0.33

Next Earnings

Nov 5, 2026

Overview News Insider Transactions Government Trades Fundamentals

Aptevo Therapeutics Inc. stock is down -58.59% since 30 days ago. The next earnings date is Nov 5, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 9.09% of the previous 10 September’s closed higher than August.

Benzinga Newsdesk

Wed Aug 12, 2026

Aptevo Therapeutics shares are trading lower. The company announced exercise of existing warrants and PIPE for $4.5 million gross proceeds.
Benzinga Newsdesk

Mon Jul 27, 2026

Reported Earlier: Aptevo Therapeutics Announces A New Solid Strategy Designed To Fight Cancer On Multiple Fronts; Files A Patent Application Covering A Proprietary Nectin-4 X PD-L1 Dual-Targeting Backbone Designed To Strengthen Aptevo's Oncology Pipeline

Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced a new solid tumor strategy designed to fight cancer on multiple
Benzinga Insights

Thu Jul 9, 2026

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's pre-market session. The company's market cap stands at $2.5 million. Alnylam Pharmaceuticals (NASDAQ:ALNY) stock
Avi Kapoor

Thu Jul 9, 2026

Why Ultra Clean Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket

Stocks moving: RPGL +54.5%, EDBL +42.5%, SDOT +27.4%, BJDX +24.6%, AP +19.9%, SUNE +18%, ALNY +15.3%, AIBZ +14.3%, BBIO +10%. Losers: AFJK -25.8%, VTAK -19%, APVO -18%, NQ -16.3%.
Benzinga Insights

Wed Jul 8, 2026

12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-market session. The company's market cap stands at $11.0 million. BioRestorative Therapies (NASDAQ:BRTX) stock moved
Benzinga Newsdesk

Wed Jul 8, 2026

Aptevo Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "4-1BB AND OX40 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS, ANTIBODIES AGAINST 4-1BB, ANTIBODIES AGAINST OX40 (FOR THE TREATMENT OF CANCER)".

https://patentcenter.uspto.gov/applications/17634631/ifw/docshttps://x.com/PatentGrants/status/2074946217625493850
Benzinga Newsdesk

Tue Jun 30, 2026

Andy Hill Cancer Research Endowment Awards Aptevo Therapeutics $1.5M Non-Dilutive Research Grant For APVO451.
Benzinga Newsdesk

Wed May 27, 2026

Aptevo Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS (FOR THE TREATMENT OF PROSTATE CANCER)".

https://patentcenter.uspto.gov/applications/16871597/ifw/docshttps://x.com/PatentGrants/status/2059725536650547305
Benzinga Newsdesk

Wed May 27, 2026

Aptevo Therapeutics Partners With Niowave To Develop Up To Three Radiopharmaceutical Oncology Programs

Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform
Benzinga Newsdesk

Wed May 6, 2026

Aptevo Therapeutic Announces 87% Clinical Benefit Rate And 81% Remission Rate In Its RAINIER Frontline Acute Myeloid Leukemia Trial, RAINIER Remains On Schedule For 2026 Completion And Phase 2 Dose Selection

The Company is on track to complete the Phase 1b dose-optimization trial and select the recommended Phase 2 dose (RP2D) this year. As with the current study, the Phase 2 trial will dose mipletamig in combination with venetoclax and azacitidine.

Zsolt Harsanyi, Insider

Thu Aug 6, 2026

APVO Recent Insider Trades and Stock Chart

400 shares converted
Jeffrey Lamothe, President and CEO

Thu Aug 6, 2026

APVO Recent Insider Trades and Stock Chart

961 shares converted
Daphne Taylor, SVP

Thu Aug 6, 2026

APVO Recent Insider Trades and Stock Chart

638 shares converted
SoYoung Kwon, SVP

Thu Aug 6, 2026

APVO Recent Insider Trades and Stock Chart

638 shares converted
Dirk Huebner, SVP

Thu Aug 6, 2026

APVO Recent Insider Trades and Stock Chart

638 shares converted
Grady Grant III, Insider

Thu Aug 6, 2026

APVO Recent Insider Trades and Stock Chart

400 shares converted
Marvin White, Executive Chair

Thu Aug 6, 2026

APVO Recent Insider Trades and Stock Chart

1,666 shares converted
Daniel AbdunNabi, Insider

Thu Aug 6, 2026

APVO Recent Insider Trades and Stock Chart

400 shares converted
Lopez Barbara Kunz, Insider

Thu Aug 6, 2026

APVO Recent Insider Trades and Stock Chart

400 shares converted
John Niederhuber, Insider

Thu Aug 6, 2026

APVO Recent Insider Trades and Stock Chart

400 shares converted
Marvin White, Executive Chair

Fri Jul 17, 2026

APVO Recent Insider Trades and Stock Chart

1 shares converted